ANZCTR search results

We aim to assess the effect of two types of individualised education and exercise programs to determine if they can improve neck disability in people with chronic neck pain. Both groups will receive between 2-8 one-on-one treatment sessions with an allied health clinician via telehealth. The study design will be a nation-wide randomised controlled trial. The primary outcome is neck disability at 12 weeks. Cost-effectiveness of the treatments will also be evaluated.

This study aims to evaluate whether the ElectroPulse PFA System (which delivers energy to scar areas of the heart tissue causing abnormal rhythms, so the heart beats normally again) is a safe and effective treatment for people with atrial fibrillation (AF), a common heart rhythm disorder. The results will help support global regulatory approval of the system.

The safety, efficacy and Pharmacokinetics of PTC844 tablets will be assessed with multiple doses over a period of 14 days followed by a single dose. This will be a randomised, double-blind study in healthy volunteers taking standard meal..

This trial is a treatment specific appendix in a modular component of the Precision Therapies in Monogenic Epilepsies (PRIME) master protocol, for a series of N-of-1 studies of precision therapies in monogenic epilepsies. It uses a within-participant, controlled, multi-crossover design to test the hypothesis that Riluzole, a blocker of the neuronal persistent sodium current, improves seizure frequency in individuals with SCN8A-DEE caused by gain-of-function (GoF) variants in the voltage-gated sodium channel alpha subunit 8 gene SCN8A. Plain English summary: This study tests whether the drug riluzole can reduce seizures in people with SCN8A developmental and epileptic encephalopathy (SCN8A-DEE) caused by gain-of-function changes in the SCN8A gene. Each participant will try both the drug and a placebo at different times, so their own results can be compared directly.

Primary aim of this research is to evaluate the impact of the Supportive Care in Chronic Disease (SCCD) model on health service utilisation and consumer experience among patients with liver disease, heart failure, Parkinson’s disease, motor neurone disease, chronic obstructive pulmonary disease, and for patients within the Integrated Chronic Care for Aboriginal People Programs (ICCAPP), with a prognosis of 2 years or less, and their carers.

The primary aim of the project is to evaluate the implementation, effectiveness and acceptability of using an immersive Virtual Reality (VR) pain education program at Queensland’s tertiary adult persistent pain management services. It is hypothesized that the use of a Virtual Reality based pain education program will an acceptable and helpful treatment option to improve outcomes for people with chronic pain.

The purpose of this study is to assess if the movement of the CPAP pressure meter while the participant is breathing can be used to determine the size of the breath. We will compare the movement to the amount of air your baby breathes, measured by the breathing monitor attached to the CPAP tubing. We currently do not have information about whether there is a link between the movement of the meter and the amount of air the participant is breathing, if there is this could be important information for babies who need breathing support at birth.

The prevalence of obesity in patients with T1D is increasing. The common consequences of obesity in individuals with T1D include, insulin resistance, increased insulin requirements and impaired glycaemic control, increasing the risk of diabetes-related complications in these individuals. Novel therapeutic strategies that reduce body weight and synergistically aid insulin therapy in improving glycaemic control are therefore needed to address this challenge and reduce their risk of life-threatening diabetic complications. Tirzepatide is an incretin-based therapy commonly used in patients with type 2 diabetes and/or obesity that has proven effective for reducing body weight and improving glycaemic control. Therefore, this study aims to evaluate the efficacy of tirzepatide in individuals with concurrent T1D and overweight or obesity who are receiving insulin therapy in a cross-over randomised study design. The aim is to evaluate if adjunctive insulin therapy with tirzepatide can lead to a reduction in body weight and improved metabolic outcomes compared to insulin treatment alone.

The lmmunoPET study aims to assess whether it is feasible to use 89Zr-durvalumab (89Zr-durva) as a PET tracer of PD-L1 (a cancer related protein) in patients with cancer. Who is it for? You may be eligible for this study if you are an adult with non-small cell lung cancer. Study details All participants will receive an injection in the arm containing the 89Zr-durva tracer about 3 days prior to completing a PET scan. Each PET scan will take approximately 30 minutes. This infusion will take place at three timepoints: before radiotherapy, 14 days after starting radiotherapy and approximately 42 days after radiotherapy treatment has finished. Blood tests will be taken at each of these PET scans. About 15 to 2oml of blood will be taken at each PET scan. It is hoped that this study will help determine if 89Zr-durvalumab (89Zr-durva) is a feasible option for use as a tracer of PD-L1.

Older adults often struggle to breathe deeply after breaking ribs because pain makes every breath hurt. This study will test whether adding an ultrasound-guided erector spinae plane (ESP) block—a small catheter that drips numb­ing medicine beside the spine—can improve breathing and comfort beyond what usual pain medicines alone achieve. Twenty patients aged 65 years or older with recent rib fractures will be randomly allocated to (1) ESP catheter + standard medicines or (2) standard medicines alone. Lung function metrics; FEV1, PEFR and FVC, will be checked with a hand-held spirometer before treatment and once daily for five days, and participants will be phoned at 30 days to discuss their recovery. Study hypothesis: patients who receive the ESP catheter will show a greater day-to-day improvement in lung function, report less pain, and need fewer opioids than those receiving standard care alone.